120 related articles for article (PubMed ID: 28003677)
1. Two Relapsed Stage III Childhood Anaplastic Large Cell Lymphoma Patients with NPM-ALK Fusion in Bone Marrow from Initial Diagnosis.
Kanazawa Y; Yamashita Y; Fujiwara M; Muraoka M; Washio K; Kanamitsu K; Ishida H; Nakano T; Yamada M; Horibe K; Tanaka T; Yoshino T; Shimada A
Acta Med Okayama; 2016 Dec; 70(6):503-506. PubMed ID: 28003677
[TBL] [Abstract][Full Text] [Related]
2. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
3. Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma.
Damm-Welk C; Mussolin L; Zimmermann M; Pillon M; Klapper W; Oschlies I; d'Amore ES; Reiter A; Woessmann W; Rosolen A
Blood; 2014 Jan; 123(3):334-7. PubMed ID: 24297868
[TBL] [Abstract][Full Text] [Related]
4. Story of survival in anaplastic large cell lymphoma - sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases.
Agrawal K; Shet T; Sridhar E; Dhende S; Sengar M; Arora B; Laskar S; Gujral S; Menon H; Banavali S
Indian J Pathol Microbiol; 2017; 60(4):533-540. PubMed ID: 29323068
[TBL] [Abstract][Full Text] [Related]
5. Anaplastic large cell lymphoma: a single institution experience from India.
Lakshmaiah KC; Guruprasad B; Shah A; Kavitha S; Abraham LJ; Govindbabu K; Aruna Kumari BS; Appaji L
J Cancer Res Ther; 2013; 9(4):649-52. PubMed ID: 24518711
[TBL] [Abstract][Full Text] [Related]
6. Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma.
K Singh V; Werner S; Hackstein H; Lennerz V; Reiter A; Wölfel T; Damm-Welk C; Woessmann W
Clin Exp Immunol; 2016 Oct; 186(1):96-105. PubMed ID: 27414060
[TBL] [Abstract][Full Text] [Related]
7. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
[TBL] [Abstract][Full Text] [Related]
8. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
9. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow involvement in NPM-ALK-positive lymphoma: report of two cases.
Sadahira Y; Hata S; Sugihara T; Manabe T
Pathol Res Pract; 1999; 195(9):657-61. PubMed ID: 10507087
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic significance of the NPM-ALK fusion gene in bone marrow and peripheral blood for patients with anaplastic large cell lymphoma].
Yang J; Zhao XX; Jin L; Duan YL; Huang S; Zhang M; Zhang R; Zhou CJ; Zhang YH
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):700-3. PubMed ID: 23978023
[TBL] [Abstract][Full Text] [Related]
12. Fatal ALK-negative systemic anaplastic large cell lymphoma presenting with disseminated cutaneous dome-shaped papules and nodules.
Bird JE; Leitenberger JJ; Solomon A; Blauvelt A; Hopkins S
Dermatol Online J; 2012 May; 18(5):5. PubMed ID: 22630575
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometric detection of circulating tumour cells in nucleophosmin/anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: comparison with quantitative polymerase chain reaction.
Damm-Welk C; Schieferstein J; Schwalm S; Reiter A; Woessmann W
Br J Haematol; 2007 Aug; 138(4):459-66. PubMed ID: 17608768
[TBL] [Abstract][Full Text] [Related]
14. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma.
Iijima-Yamashita Y; Mori T; Nakazawa A; Fukano R; Takimoto T; Tsurusawa M; Kobayashi R; Horibe K
Int J Hematol; 2018 Feb; 107(2):244-250. PubMed ID: 29030834
[TBL] [Abstract][Full Text] [Related]
16. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.
Mitou G; Frentzel J; Desquesnes A; Le Gonidec S; AlSaati T; Beau I; Lamant L; Meggetto F; Espinos E; Codogno P; Brousset P; Giuriato S
Oncotarget; 2015 Oct; 6(30):30149-64. PubMed ID: 26338968
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic large cell lymphoma, ALK-positive.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2012 Aug; 83(2):293-302. PubMed ID: 22440390
[TBL] [Abstract][Full Text] [Related]
18. Detection of a TRAF1-ALK fusion in an anaplastic large cell lymphoma patient with chemotherapy and ALK inhibitor-resistant disease.
Lawrence K; Berry B; Handshoe J; Hout D; Mazzola R; Morris SW; Saltman DL
BMC Res Notes; 2015 Jul; 8():308. PubMed ID: 26187744
[TBL] [Abstract][Full Text] [Related]
19. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
Foyil KV; Bartlett NL
Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
[TBL] [Abstract][Full Text] [Related]
20. [ATIC-ALK-positive anaplastic large cell lymphoma: a case report and review of the literature].
Matsubara K; Tanaka T; Taki T; Nakagawa A; Nigami H; Tamura A; Fukaya T
Rinsho Ketsueki; 2008 May; 49(5):325-30. PubMed ID: 18572809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]